Skip to content

Developmental and Epileptic Encephalopathy of Genetic Etiology: Natural History Through Reuse of Clinical Data

Developmental and Epileptic Encephalopathy of Genetic Etiology: Natural History Through Reuse of Clinical Data / DEE-RETRO

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06380192
Acronym
DEE-RETRO
Enrollment
400
Registered
2024-04-23
Start date
2024-10-31
Completion date
2026-12-31
Last updated
2025-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Developmental and Epileptic Encephalopathy

Brief summary

Developmental and Epileptic Encephalopathy (DEE) are a heterogeneous group of neurodevelopmental disorders linked to both epilepsy and its underlying etiology, independently of epileptiform activity. The creation of a database with retrospective follow-up of a large number of patients on a national scale will enable better knowledge of specific biomarkers, and thus a better classification and understanding of the natural evolution of DEE according to their etiology. This will enable better, more personalized therapeutic management of patients, depending on etiology and the presence or absence of these biomarkers. The investigators will also be able to draw up management recommendations, which are currently non-existent.

Interventions

None listed

Sponsors

Imagine Institute
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Developmental and Epileptic Encephalopathy * Registered with or benefiting from a social security scheme.

Exclusion criteria

* Opposition of the patient or his/her parents to the re-use of data in the context of this study * Person subject to a safeguard of justice measure

Design outcomes

Primary

MeasureTime frameDescription
Identification of diagnostic and early predictive biomarkers of a neurodevelopmental trajectory with epileptic and developmental encephalopathiesData 2002-2026This composite outcome includes multiple diagnostic domains (Clinical, biological, radiological, genetic and electroencephalographic variables)

Secondary

MeasureTime frameDescription
Identification of patient subgroups presenting the identified biomarkersData 2002-2026To identify patient subgroups, correlation analyses will be carried out to highlight any common clinical, biological, genetic, radiological and electroencephalographic findings.
Assessment of patients' quality of lifeData 2002-2026The SF-12 questionnaire is used to assess quality of life.
Assessment of age-related adaptive behaviorData 2002-2026To assess the age of adaptive behavior, the Vineland II scale is the reference test.
Assessment of behavioral disordersData 2002-2026The CBCL (Child Behaviour Checklist) questionnaire is the reference test for assessing behavioural problems.
Assessment of autism spectrum disordersData 2002-2026The Social Communication Questionnaire (SCQ) will be used to assess autism spectrum disorders.

Countries

France

Contacts

Primary ContactRima Nabbout, Pr
rima.nabbout@aphp.fr+33144381536

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026